Teva Sub Says It Should Also Be Cut From FTC Androgel Suit

By Eric Kroh (February 8, 2017, 4:50 PM EST) -- Teva subsidiary Actavis Holdco Inc. told a Georgia federal court Tuesday the government's dismissal of Par Pharmaceuticals Inc. supports its own bid to exit a lawsuit by the U.S. Federal Trade Commission alleging pharmaceutical companies illegally conspired to delay generic competition for AndroGel.

Just as the FTC said Par should be let go because it was already subject to a court injunction prohibiting it from entering into the reverse payment agreements that are at issue in the case, Actavis Holdco US Inc. is likewise barred by a similar injunction on Teva and should be granted summary judgment, the company said....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!